{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.94","value":"-0.6"},{"groupId":"OG001","spread":"2.94","value":"-1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"163"}],"units":"Participants"}],"title":"Week 4 (n=170,163)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.02","value":"-1.1"},{"groupId":"OG001","spread":"3.76","value":"-1.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"136"}],"units":"Participants"}],"title":"Week 10 (n=133,136)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.42","value":"-1.2"},{"groupId":"OG001","spread":"3.50","value":"-2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"title":"Week 16 (n=114,126)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.25","value":"-1.3"},{"groupId":"OG001","spread":"3.52","value":"-2.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"108"}],"units":"Participants"}],"title":"Week 22 (n=105,108)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"163"}],"units":"Participants"}],"description":"The SQLQ consists of 5 items assessing the worst mouth/throat, hand, and foot soreness, and limitations due to mouth/throat and foot soreness. Participants assessed the limitations caused by their foot soreness by answering the question of \"In the past 4 weeks, how much did your worst foot soreness limit you in each of the following activities: standing/walking/climbing stairs/sleeping/ability to do usual activities\" by using the following 4-point scale: 0, not limited; 1, limited a little; 2, limited a lot; 3, unable to do. The overall limitation score (15=best; 0=worst), based on the individual scores for the 5 activities, is derived as follows: the actual scores were rescored by subtracting the actual score from \"3\" for each of the 5 categories. A high score indicates less limitation. Change from Baseline was calculated as the assessment week value minus the Baseline value. A negative mean change from Baseline represents a worsening of condition.","dispersionType":"Standard Deviation","groups":[{"description":"Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG000","title":"Pazopanib 800 mg"},{"description":"Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG001","title":"Sunitinib 50 mg"}],"paramType":"MEAN","populationDescription":"Intent-to-Treat (ITT) Population. Analysis was based on the assigned randomized treatment, not on the actual treatment received/not received. Some participants were missing scores at Baseline and were excluded from the analysis. Participants missing scores at other early time points were excluded from the analysis at those time points.","reportingStatus":"POSTED","timeFrame":"Baseline (predose), Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)","title":"Change From Baseline in the Supplementary Quality of Life Questions (SQLQ) Limitations Due to Foot Soreness Scores at Day 28 of Cycles 1-4","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}